BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:7MW3711 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 7MW3711\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07466160-2299@assetmemo.bio
DTSTAMP:20261121T005850Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:7MW3711: Phase 1/2 readout est. (NCT07466160)
DESCRIPTION:7MW3711\, phase 1/2.\nStudy: A Phase Ib/II Study of 7MW3711 Com
 bined With JS207 in Advanced Solid Tumors\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/7mw3
 711#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07466160
URL:https://assetmemo.bio/drug/7mw3711#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831863-2299@assetmemo.bio
DTSTAMP:20261121T005850Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:7MW3711: Phase 3 readout est. (NCT07831863)
DESCRIPTION:7MW3711\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study
  of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior
  Chemoimmunotherapy\nEstimated primary completion: March 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/7mw3711#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07831863
URL:https://assetmemo.bio/drug/7mw3711#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
